Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Operating income | -$8.91K | -$14.7K | -$3.18M | -$64.8K | -$95.8K | -$76.4K |
| Net income | -$8.91K | -$14.7K | -$3.18M | -$64.8K | -$95.8K | -$76.4K |
| EPS (diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.91K | $14.7K | $33.7K | -$64.8K | -$155K | -$79.7K |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.61K | $399.00 | $864.00 | $19.6K | $2.08K | $1.89K |
| Total assets | $1.61K | $399.00 | $864.00 | $19.6K | $17.9K | $21.0K |
| Total liabilities | $10.5K | $24.0K | $18.2K | $102K | $239K | $319K |
| Shareholders' equity | -$8.91K | -$23.6K | -$17.3K | -$82.1K | -$221K | -$298K |
| Retained earnings | $137K | $152K | -$3.34M | -$3.40M | -$8.93M | -$9.00M |
| Shares (wtd avg diluted) | 13.2M | 396M | 724M | 876M | 1.02B | 1.05B |
Every figure is extracted from NIKA PHARMACEUTICALS, INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.